Type of non Hodgkin's lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Diffuse large B-cell lymphoma Posts on Medivizor

What factors can predict the success of stem cell transplantation for patients with non-Hodgkin lymphoma?

Posted by on Nov 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...

Read More

Can FDG-PET/CT scanning predict treatment outcomes in diffuse large B-cell lymphoma?

Posted by on Oct 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated whether FDG-PET/CT imaging during treatment helped predict outcomes for patients with diffuse large B-cell lymphoma (DLBCL). The authors concluded that mid-treatment imaging might help determine disease status rather than guide treatment decisions. Some background DLBCL is the most common type of...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Evaluating blinatumomab for patients with recurrent or non-responsive non-Hodgkin’s lymphoma

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the long-term safety and effectiveness of blinatumomab (Blincyto) for non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The authors concluded that blinatumomab showed promising effectiveness for these patients, with minimal side effects. Some background Chemoimmunotherapy...

Read More

Evaluating the risk of secondary cancers from infections in patients with non-Hodgkin’s lymphoma

Posted by on Aug 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether there is a link between the type of non-Hodgkin’s lymphoma (NHL) and the development of secondary cancer due to certain infections.  The authors concluded that patients with diffuse large B-cell lymphoma (DLBCL) or marginal zone lymphoma (MZL) may be at risk for developing a second type of...

Read More

Using liver AST levels to predict outcomes for patients with diffuse large B-cell lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the impact of aspartic transaminase (AST) levels in the blood on survival outcomes for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that high levels of AST in the blood were associated with poorer treatment outcomes for these patients. Some background DLBCL is one of the most common types...

Read More

Evaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma

Posted by on Jun 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...

Read More

Evaluating polatuzumab vedotin with chemoimmunotherapy for diffuse large B-cell lymphoma

Posted by on Jun 5, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of polatuzumab vedotin (Pola) combined with chemoimmunotherapy for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that combining Pola with these regimens was promising, with manageable side effects. Some background DLBCL is one of the most common types...

Read More

Evaluating the FMT regimen before a stem cell transplant in patients with aggressive non-Hodgkin lymphoma

Posted by on May 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of the FMT (fludarabine, melphalan, total body irradiation) regimen in patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that this regimen was well-tolerated and effective. Some background Many patients with aggressive NHL...

Read More

Searching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.

Posted by on May 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...

Read More

Evaluating polatuzumab vedotin and pinatuzumab vedotin for relapsed or refractory NHL

Posted by on May 20, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) combined with either polatuzumab vedotin (pola) or pinatuzumab vedotin (pina) for patients with non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. This study concluded that pola was associated with better...

Read More